Actively Recruiting
A Prospective Cohort Study of Metabolic Associated Fatty Liver Disease in China
Led by Nanfang Hospital, Southern Medical University · Updated on 2021-02-09
3000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to better understand metabolic dysfunction-associated fatty liver disease (MAFLD), a condition defined by fatty liver with metabolic risks like obesity, diabetes, or metabolic problems. The study also seeks to compare MAFLD with non-alcoholic fatty liver disease (NAFLD), including patients who have liver fat but no metabolic risk, and those with both MAFLD and other liver diseases. The goal is to clarify clinical features and improve diagnosis and outcomes for these patients. The study includes two parts: first, a cross-sectional analysis collecting clinical data from patients with fatty liver to examine their characteristics; second, a long-term follow-up involving collection of plasma, urine, and stool samples to identify biomarkers that help predict disease progression and patient stratification. The trial will observe patients over time to assess these factors. Participants will undergo clinical data collection and sample provision, with researchers monitoring for outcomes such as all-cause death over 10 years. They will also track liver-related complications and other important health issues like cardiovascular disease. The study aims to understand how different metabolic factors relate to disease progression. This long-term observational approach will provide insights to inform better management of MAFLD and NAFLD.
CONDITIONS
Brief Title
A Prospective Cohort Study of Metabolic Associated Fatty Liver Disease in China
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed as hepatic steatosis in adults with at least one of the following: liver ultrasound showing "bright liver", controlled attenuation-parameter ≥248 dB/m, hepatic steatosis diagnosed by CT/MRI/MRS, MRI-based proton-density fat fraction showing liver fat content >8%, or fatty liver confirmed by liver histology.
You will not qualify if you...
- Diagnosed with hepatocellular carcinoma or other malignancy
- Currently pregnant
- History of liver transplantation
- History of serious cardiovascular or cerebrovascular events such as acute myocardial infarction, cerebral infarction, or cerebral hemorrhage
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Initial cross-sectional assessment
Participants provide clinical data and samples including plasma, urine, and stool to assess fatty liver and related metabolic features.
1 visit (in-person)
Duration - Up to 10 years
Participants are followed to monitor disease progression, liver-related complications, and overall health outcomes.
Periodic visits over 10 years
Trial Site Locations
Total: 1 location
1
Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510515
Actively Recruiting
Research Team
J
Jinjun Chen
L
Ling Zhou
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here